Project: Microglia/neuron crosstalk in autism spectrum disorder: Role of early inflammatory activation

Acronym	MINERVA (Reference Number: NEURON_NDD-184)
Project Topic	Our knowledge on how microglia shape brain excitatory/inhibition (E/I) balance and whether it is disturbed by early maternal infections or genetic factors and accessible for new therapeutic interventions in autism spectrum disorders (ASD), especially in humans, remains elusive. MINERVA takes advantage of deeply phenotyped patient cohort, novel human stem cell -based models and in vivo models with sensitive behavioral readouts to investigate how maternal infection and genetic risk factors interact and drive microglia activation patterns resulting in GABAergic mediated E/I balance and neurodevelopmental disturbances. We reproduce ASD profile in human cellular and animal models to identify mechanisms and stimuli that disrupt normal neurodevelopment and accelerate the severity of resulting ASD phenotypes. MINERVA creates a basis for novel treatments correcting abnormal network maturation, targeting either abnormal GABAergic drive via KCC2 transporters, or disease immune signature. From a small cohort of ASD patients stratified, by immune signature we will bring new, clinically translatable principles of the ASD therapy amenable for large patient groups. MINERVA promotes meaningful involvement of Individuals with ASD in all steps of research including study design, conduct and dissemination to better address the clinical needs fo individuals with ASD. These activities provide feedback on challenges, ethical issues and social engagement linked to participant involvement.
Network	NEURON Cofund2
Call	Neuron Cofund2 Joint Call 2021

Project partner

Number	Name	Role	Country
1	University of Eastern Finland	Coordinator	Finland
2	KU Leuven	Partner	Belgium
3	Philipps-University of Marburg	Partner	Germany
4	University Hospital of Münster	Partner	Germany
5	Istituto Superiore di Sanità	Partner	Italy